BioSpace

Amgen starts MariTide autoinjector study as pivotal readouts approach

With the first Phase 3 data expected for Amgen’s MariTide next year, analysts are looking for evidence that the GLP-1 candidate is tolerable. Meanwhile, the company has begun testing an autoinjector formulation.

By BioSpace

1 min read
Amgen starts MariTide autoinjector study as pivotal readouts approach
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights